|
US6855510B2
(en)
*
|
2001-03-20 |
2005-02-15 |
Dana Farber Cancer Institute, Inc. |
Pharmaceuticals and methods for treating hypoxia and screening methods therefor
|
|
JP4590157B2
(ja)
*
|
2001-03-21 |
2010-12-01 |
アイシス イノヴェイション リミテッド |
アッセイ、方法および手段
|
|
EP2295060B1
(en)
|
2001-12-06 |
2018-10-31 |
Fibrogen, Inc. |
Treatment or prevention of ischemic or hypoxic conditions
|
|
US8318703B2
(en)
|
2001-12-06 |
2012-11-27 |
Fibrogen, Inc. |
Methods for improving kidney function
|
|
HU229475B1
(en)
|
2001-12-06 |
2014-01-28 |
Fibrogen |
Methods of increasing endogenous erythropoietin (epo)
|
|
US7618940B2
(en)
|
2002-12-06 |
2009-11-17 |
Fibrogen, Inc. |
Fat regulation
|
|
US8124582B2
(en)
|
2002-12-06 |
2012-02-28 |
Fibrogen, Inc. |
Treatment of diabetes
|
|
CN103145616B
(zh)
|
2003-06-06 |
2015-09-30 |
菲布罗根有限公司 |
含氮杂芳基化合物及其在增加内源性促红细胞生成素中的用途
|
|
US8614204B2
(en)
*
|
2003-06-06 |
2013-12-24 |
Fibrogen, Inc. |
Enhanced erythropoiesis and iron metabolism
|
|
WO2005007192A2
(en)
*
|
2003-06-06 |
2005-01-27 |
Fibrogen, Inc. |
Cytoprotection through the use of hif hydroxylase inhibitors
|
|
EP1658074B1
(en)
*
|
2003-08-01 |
2012-11-07 |
Fibrogen, Inc. |
Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
|
|
WO2005034929A2
(en)
*
|
2003-10-10 |
2005-04-21 |
Fibrogen, Inc. |
Tissue remodeling and vascularization
|
|
US20050136125A1
(en)
*
|
2003-10-22 |
2005-06-23 |
Roth Mark B. |
Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
|
|
CA2542426A1
(en)
*
|
2003-10-22 |
2005-05-06 |
Fred Hutchinson Cancer Research Center |
Methods, compositions and devices for inducing stasis in cells
|
|
US20050170019A1
(en)
*
|
2003-10-22 |
2005-08-04 |
Fred Hutchinson Cancer Research Center |
Methods, compositions and devices for inducing stasis in cells
|
|
US7248843B2
(en)
*
|
2003-11-07 |
2007-07-24 |
Ge Medical Systems Information Technologies, Inc. |
Antenna selection system and method
|
|
EP1548031A1
(en)
*
|
2003-12-22 |
2005-06-29 |
Dubai Genetics FZ-LLC |
Nature-identical erythropoietin
|
|
US20050282751A1
(en)
*
|
2004-03-19 |
2005-12-22 |
Ajinomoto Co., Inc. |
Therapeutic agent for renal anemia
|
|
US7638295B2
(en)
*
|
2004-03-26 |
2009-12-29 |
Isis Innovation Limited |
Assays for identifying modulators of the hydroxylation of ankyrin repeat proteins by 2-oxoglutarate dependent oxygenase and methods of using the same
|
|
AU2005250412B2
(en)
*
|
2004-05-28 |
2009-09-17 |
Fibrogen, Inc. |
HIF prolyl hydroxylase activity assay
|
|
US7718624B2
(en)
*
|
2004-09-01 |
2010-05-18 |
Sitkovsky Michail V |
Modulation of immune response and inflammation by targeting hypoxia inducible factors
|
|
US20060074182A1
(en)
*
|
2004-09-30 |
2006-04-06 |
Depuy Products, Inc. |
Hydrogel composition and methods for making the same
|
|
US20080213404A1
(en)
*
|
2005-02-04 |
2008-09-04 |
Johnson Randall S |
Hif Modulating Compounds and Methods of Use Thereof
|
|
US8703795B2
(en)
|
2005-03-02 |
2014-04-22 |
Fibrogen, Inc. |
Thienopyridine compounds, and methods of use thereof
|
|
AR055319A1
(es)
*
|
2005-03-17 |
2007-08-15 |
Wyeth Corp |
Derivados de isoquinoleina, composiciones farmaceuticas y usos
|
|
PT1879599E
(pt)
*
|
2005-04-20 |
2014-01-23 |
Hutchinson Fred Cancer Res |
Métodos, composições e artigos de fabrico para aumentar a capacidade de sobrevivência de células, tecidos, órgãos, e organismos
|
|
DE102005019712A1
(de)
*
|
2005-04-28 |
2006-11-09 |
Bayer Healthcare Ag |
Dipyridyl-dihydropyrazolone und ihre Verwendung
|
|
CN101849943A
(zh)
*
|
2005-06-06 |
2010-10-06 |
菲布罗根公司 |
使用HIFα稳定剂的改进的贫血治疗
|
|
AU2006259352A1
(en)
|
2005-06-15 |
2006-12-28 |
Fibrogen, Inc. |
Use of HIF 1alfa modulators for treatment of cancer
|
|
GB0519605D0
(en)
*
|
2005-09-26 |
2005-11-02 |
Isis Innovation |
Assay
|
|
WO2007038571A2
(en)
*
|
2005-09-26 |
2007-04-05 |
Smithkline Beecham Corporation |
Prolyl hydroxylase antagonists
|
|
WO2007047194A2
(en)
*
|
2005-10-11 |
2007-04-26 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating mitf-related disorders
|
|
CN100418574C
(zh)
*
|
2005-10-26 |
2008-09-17 |
王成球 |
一类封闭人类HIF-1α基因和调控网络中下游相关基因的染色质肽
|
|
BRPI0618947B1
(pt)
|
2005-11-23 |
2022-07-19 |
Acceleron Pharma Inc |
Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea
|
|
US8128933B2
(en)
|
2005-11-23 |
2012-03-06 |
Acceleron Pharma, Inc. |
Method of promoting bone growth by an anti-activin B antibody
|
|
US20070122448A1
(en)
*
|
2005-11-28 |
2007-05-31 |
Alireza Rezania |
Compositions and methods to create a vascularized environment for cellular transplantation
|
|
AU2006326662B2
(en)
*
|
2005-12-09 |
2011-07-28 |
Amgen Inc. |
Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof
|
|
CN102351791B
(zh)
|
2006-01-27 |
2014-10-29 |
菲布罗根有限公司 |
使低氧诱导因子(hif)稳定的氰基异喹啉化合物
|
|
US20070185045A1
(en)
*
|
2006-02-06 |
2007-08-09 |
Ratcliffe Peter J |
Inhibitors of 2-oxoglutarate dioxygenase as gamma globin inducers
|
|
US20070259960A1
(en)
*
|
2006-02-16 |
2007-11-08 |
Fibrogen, Inc. |
Compounds and methods for treatment of stroke
|
|
US7588924B2
(en)
|
2006-03-07 |
2009-09-15 |
Procter & Gamble Company |
Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
|
|
AU2007234408B2
(en)
*
|
2006-04-04 |
2011-05-19 |
Fibrogen, Inc. |
Pyrrolo- and thiazolo-pyridine compounds as HIF modulators
|
|
US7713986B2
(en)
|
2006-06-15 |
2010-05-11 |
Fibrogen, Inc. |
Compounds and methods for treatment of chemotherapy-induced anemia
|
|
US20070293575A1
(en)
*
|
2006-06-15 |
2007-12-20 |
Fibrogen, Inc. |
Compounds and methods for treatment of cancer-related anemia
|
|
TWI394747B
(zh)
*
|
2006-06-23 |
2013-05-01 |
Smithkline Beecham Corp |
脯胺醯基羥化酶抑制劑
|
|
NZ623002A
(en)
|
2006-06-26 |
2015-08-28 |
Akebia Therapeutics Inc |
Prolyl hydroxylase inhibitors and methods of use
|
|
US8454948B2
(en)
|
2006-09-14 |
2013-06-04 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
|
JP2010504909A
(ja)
|
2006-09-14 |
2010-02-18 |
メドジェニクス・メディカル・イスラエル・リミテッド |
長期持続性の医薬製剤
|
|
US20090011051A1
(en)
*
|
2006-09-28 |
2009-01-08 |
Roth Mark B |
Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds
|
|
WO2008076427A2
(en)
*
|
2006-12-18 |
2008-06-26 |
Amgen Inc. |
Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
|
|
US8895016B2
(en)
|
2006-12-18 |
2014-11-25 |
Acceleron Pharma, Inc. |
Antagonists of activin-actriia and uses for increasing red blood cell levels
|
|
US8048892B2
(en)
|
2006-12-18 |
2011-11-01 |
Amgen Inc. |
Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
|
|
WO2008086025A2
(en)
*
|
2007-01-10 |
2008-07-17 |
Edison Pharmaceuticals, Inc. |
Treatment of respiratory chain disorders using compounds having erythropoietin or thrombopoietin activity
|
|
CL2008000066A1
(es)
|
2007-01-12 |
2008-08-01 |
Smithkline Beecham Corp |
Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
|
|
TW200845994A
(en)
*
|
2007-01-12 |
2008-12-01 |
Smithkline Beecham Corp |
N-substituted glycine derivatives: prolyl hydroxylase inhibitors
|
|
US7601399B2
(en)
|
2007-01-31 |
2009-10-13 |
Surface Modification Systems, Inc. |
High density low pressure plasma sprayed focal tracks for X-ray anodes
|
|
TW201627320A
(zh)
|
2007-02-02 |
2016-08-01 |
艾瑟勒朗法瑪公司 |
衍生自ActRIIB的變體與其用途
|
|
US7618938B2
(en)
*
|
2007-02-07 |
2009-11-17 |
Academia Sinica |
Treating cerebrovascular diseases with erythropoietin and granulocyte-colony stimulating factor jointly
|
|
EP2142509B1
(en)
|
2007-04-18 |
2013-12-04 |
Amgen, Inc |
Quinolones and azaquinolones that inhibit prolyl hydroxylase
|
|
ES2446418T3
(es)
|
2007-04-18 |
2014-03-07 |
Amgen, Inc |
Derivados de indanona que inhiben la prolil hidroxilasa
|
|
US8030346B2
(en)
*
|
2007-05-04 |
2011-10-04 |
Amgen Inc. |
Heterocyclic quinolone derivatives that inhibit prolyl hydroxylase activity
|
|
CA2685219C
(en)
|
2007-05-04 |
2012-06-19 |
Amgen Inc. |
Diazaquinolones that inhibit prolyl hydroxylase activity
|
|
FI20075320A0
(fi)
*
|
2007-05-07 |
2007-05-07 |
Panu Jaakkola |
Uusia käyttökelpoisia inhibiittoreita
|
|
US8962530B2
(en)
|
2007-06-27 |
2015-02-24 |
Regents Of The University Of Colorado |
Inflammatory bowel disease therapies
|
|
WO2009041072A1
(ja)
|
2007-09-27 |
2009-04-02 |
Kowa Company, Ltd. |
テトラヒドロキノリン化合物を有効成分とする貧血の予防及び/又は治療剤
|
|
CA2700953A1
(en)
*
|
2007-10-02 |
2009-04-09 |
Amgen Inc. |
Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
|
|
WO2009058403A1
(en)
*
|
2007-11-02 |
2009-05-07 |
Fibrogen, Inc. |
Methods for reducing blood pressure
|
|
WO2009073497A2
(en)
*
|
2007-11-30 |
2009-06-11 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
|
JP2011505367A
(ja)
*
|
2007-11-30 |
2011-02-24 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
プロリルヒドロキシラーゼ阻害剤
|
|
WO2009073669A1
(en)
|
2007-12-03 |
2009-06-11 |
Fibrogen, Inc. |
Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
|
|
US8536123B2
(en)
*
|
2008-01-09 |
2013-09-17 |
Health Onvector Inc. |
Use of blood flow parameters to monitor or control the dosing of erythropoiesis-stimulating agents
|
|
US8952160B2
(en)
|
2008-01-11 |
2015-02-10 |
Fibrogen, Inc. |
Isothiazole-pyridine derivatives as modulators of HIF (hypoxia inducible factor) activity
|
|
US8324405B2
(en)
|
2008-02-05 |
2012-12-04 |
Fibrogen, Inc. |
Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors
|
|
CA2716798A1
(en)
*
|
2008-02-25 |
2009-09-03 |
Merck Sharp & Dohme Corp. |
Tetrahydrofuropyridones
|
|
WO2009143268A2
(en)
*
|
2008-05-22 |
2009-11-26 |
Edison Pharmaceuticals, Inc. |
Treatment of mitochondrial diseases with an erythropoietin mimetic
|
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
|
DK3750552T5
(da)
|
2008-08-14 |
2024-08-26 |
Acceleron Pharma Inc |
Gdf-fælder
|
|
CN102264740B
(zh)
|
2008-08-20 |
2014-10-15 |
菲布罗根有限公司 |
一种吡咯[1,2-b]哒嗪衍生物及其作为hif调节剂的用途
|
|
WO2010024911A1
(en)
*
|
2008-08-26 |
2010-03-04 |
Fibrogen, Inc. |
Methods for increasing neurogenesis
|
|
WO2010024908A1
(en)
*
|
2008-08-26 |
2010-03-04 |
Fibrogen, Inc. |
Methods for treatment of multiple sclerosis
|
|
US10098857B2
(en)
|
2008-10-10 |
2018-10-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
|
|
WO2010056767A1
(en)
|
2008-11-14 |
2010-05-20 |
Fibrogen, Inc. |
Thiochromene derivatives as hip hydroxylase inhibitors
|
|
CA2745329C
(en)
|
2008-12-04 |
2022-07-12 |
Opko Curna, Llc |
Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
|
|
WO2010113498A1
(ja)
|
2009-03-31 |
2010-10-07 |
興和株式会社 |
テトラヒドロキノリン化合物を有効成分とする貧血の予防及び/又は治療剤
|
|
MX355042B
(es)
|
2009-06-08 |
2018-04-02 |
Acceleon Pharma Inc |
Metodos para aumentar adipositos termogenicos.
|
|
CN107267520A
(zh)
|
2009-06-12 |
2017-10-20 |
阿塞勒隆制药公司 |
截短的actriib‑fc融合蛋白
|
|
KR102170682B1
(ko)
*
|
2009-08-13 |
2020-10-28 |
악셀레론 파마 인코포레이티드 |
적혈구 수준을 증가시키기 위한 gdf 트랩과 에리트로포이에틴 수용체 활성인자의 병용
|
|
CN102639700A
(zh)
|
2009-09-30 |
2012-08-15 |
哈佛大学校长及研究员协会 |
通过调节自噬增强基因产物调节自噬的方法
|
|
WO2011048611A1
(en)
|
2009-10-07 |
2011-04-28 |
Torrent Pharmaceuticals Limited |
Novel fused pyridazine derivatives
|
|
US9205129B2
(en)
*
|
2009-10-09 |
2015-12-08 |
University Of Rochester |
Methods of treatment and screening assays for HIF-1α regulation
|
|
TWI500623B
(zh)
|
2009-10-13 |
2015-09-21 |
Torrent Pharmaceuticals Ltd |
新穎稠合噻唑及噁唑嘧啶酮
|
|
KR101665749B1
(ko)
|
2009-10-21 |
2016-10-12 |
다이이찌 산쿄 가부시키가이샤 |
5-하이드록시피리미딘-4-카르복사미드 유도체
|
|
WO2011056725A1
(en)
*
|
2009-11-05 |
2011-05-12 |
Crystalgenomics, Inc. |
Pyridine derivatives and methods of use thereof
|
|
CA2774039A1
(en)
|
2009-11-06 |
2011-05-12 |
Aerpio Therapeutics Inc. |
Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
|
|
ES2658292T3
(es)
|
2009-11-17 |
2018-03-09 |
Acceleron Pharma, Inc. |
Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular
|
|
US8541430B2
(en)
|
2009-11-27 |
2013-09-24 |
Torrent Pharmaceuticals Limited |
Fused thiazolo and oxazolo pyrimidinones
|
|
CA2800498C
(en)
|
2010-03-31 |
2021-11-16 |
The Scripps Research Institute |
Reprogramming cells
|
|
AU2011268458B2
(en)
|
2010-06-15 |
2014-06-12 |
Medgenics Medical Israel Ltd. |
Long lasting drug formulations
|
|
EP2670750B1
(en)
|
2011-02-02 |
2016-09-14 |
Fibrogen, Inc. |
Naphthyridine derivatives as inhibitors of hypoxia inducible factor
|
|
GB201102659D0
(en)
|
2011-02-15 |
2011-03-30 |
Isis Innovation |
Assay
|
|
NO2686520T3
(cg-RX-API-DMAC10.html)
|
2011-06-06 |
2018-03-17 |
|
|
|
CN103717214A
(zh)
|
2011-06-06 |
2014-04-09 |
阿克比治疗有限公司 |
用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物
|
|
GB201113101D0
(en)
|
2011-07-28 |
2011-09-14 |
Isis Innovation |
Assay
|
|
US9446031B2
(en)
|
2012-01-18 |
2016-09-20 |
National University Of Singapore |
Compositions and methods for neovascularization
|
|
WO2013134660A1
(en)
|
2012-03-09 |
2013-09-12 |
Fibrogen, Inc. |
4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors
|
|
US20150018384A1
(en)
*
|
2012-03-09 |
2015-01-15 |
Fibrogen, Inc. |
Treatment for high cholesterol
|
|
EP3470397B1
(en)
|
2012-07-16 |
2021-12-29 |
Fibrogen, Inc. |
Crystalline forms of a prolyl hydroxylase inhibitor
|
|
SG11201500234YA
(en)
*
|
2012-07-16 |
2015-02-27 |
Fibrogen Inc |
Process for making isoquinoline compounds
|
|
US8883823B2
(en)
|
2012-07-16 |
2014-11-11 |
Fibrogen, Inc. |
Crystalline forms of a prolyl hydroxylase inhibitor
|
|
RU2678117C2
(ru)
|
2012-11-02 |
2019-01-23 |
Селджин Корпорейшн |
Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений
|
|
SG10202009266PA
(en)
|
2013-01-24 |
2020-10-29 |
Fibrogen Inc |
Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid
|
|
NL2010225C2
(en)
*
|
2013-02-01 |
2014-08-04 |
Conradus Ghosal Gho |
Composition and method for preserving, transporting and storing living biological materials.
|
|
IL296484B2
(en)
|
2013-06-06 |
2025-03-01 |
Fibrogen Inc |
Pharmaceutical formulations of HIF hydroxylase inhibitor
|
|
HUE066123T2
(hu)
*
|
2013-06-13 |
2024-07-28 |
Akebia Therapeutics Inc |
Készítmények és módszerek anémia kezelésére
|
|
TWI665190B
(zh)
|
2013-11-15 |
2019-07-11 |
阿克比治療有限公司 |
{[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基}乙酸之固體型式,其組合物及用途
|
|
WO2015089416A1
(en)
*
|
2013-12-12 |
2015-06-18 |
Cornell University |
Prolylhydroxylase/atf4 inhibitors for treating neural cell injury
|
|
EP2915878A1
(en)
|
2014-03-07 |
2015-09-09 |
Institut Pasteur |
Method and device for conserving viable and functional human polymorphonuclear neutrophils
|
|
CN114699529A
(zh)
|
2014-06-13 |
2022-07-05 |
阿塞勒隆制药公司 |
用于治疗溃疡的方法和组合物
|
|
EP2977056B1
(en)
|
2014-07-11 |
2018-09-12 |
Grifols Worldwide Operations Limited |
Transferrin for use in the treatment of hypoxia inducible factor (hif)-related neurodegenerative disorders
|
|
WO2016054806A1
(en)
*
|
2014-10-10 |
2016-04-14 |
Merck Sharp & Dohme Corp. |
Substittued pyridine inhibitors of hif prolyl hydroxylase
|
|
CA2974691A1
(en)
|
2015-01-23 |
2016-07-28 |
Akebia Therapeutics, Inc. |
Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
|
|
CN106146395B
(zh)
*
|
2015-03-27 |
2019-01-01 |
沈阳三生制药有限责任公司 |
3-羟基吡啶化合物、其制备方法及其制药用途
|
|
NZ735973A
(en)
|
2015-04-01 |
2023-06-30 |
Akebia Therapeutics Inc |
Compositions and methods for treating anemia
|
|
CN105296631A
(zh)
*
|
2015-11-04 |
2016-02-03 |
吴艾霖 |
流式液相芯片急性高原病脯氨酰羟化酶基因rs480902位点检测试剂盒
|
|
US11510917B2
(en)
|
2016-02-19 |
2022-11-29 |
Cornell University |
HIF-stabilization and prevention of hyperoxia-induced neonatal lung disease
|
|
CN108245687A
(zh)
*
|
2016-12-29 |
2018-07-06 |
贾中芝 |
一种IpostC在抗肠再灌注损伤中所起作用的实验方法
|
|
US11331288B2
(en)
|
2017-09-14 |
2022-05-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Conditioning irradiated tissue for increasing vascularity
|
|
US11225660B2
(en)
*
|
2017-10-12 |
2022-01-18 |
Emory University |
Methods and compositions for managing vascular conditions using miR-483 mimics and HIF1alpha pathway inhibitors
|
|
US11713298B2
(en)
|
2018-05-09 |
2023-08-01 |
Akebia Therapeutics, Inc. |
Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
|
|
US10500318B1
(en)
*
|
2018-07-03 |
2019-12-10 |
Temple Therapeutics BV |
Dosing regimens for treating hypoxia-associated tissue damage
|
|
WO2020156571A1
(zh)
*
|
2019-02-02 |
2020-08-06 |
杭州华东医药集团新药研究院有限公司 |
一种哒嗪衍生物及其制备方法和医药用途
|
|
US11524939B2
(en)
|
2019-11-13 |
2022-12-13 |
Akebia Therapeutics, Inc. |
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
|
|
US12612367B2
(en)
|
2019-12-10 |
2026-04-28 |
Akebia Therapeutics, Inc. |
Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
|
|
WO2021216530A1
(en)
|
2020-04-20 |
2021-10-28 |
Akebia Therapeutics, Inc. |
Treatment of viral infections, of organ injury, and of related conditions using a hif prolyl hydroxylase inhibitor or a hif-alpha stabilizer
|
|
EP4674480A3
(en)
|
2020-10-02 |
2026-04-08 |
Keros Therapeutics, Inc. |
Methods of using activin receptor type ii variants
|
|
CN113826614B
(zh)
*
|
2021-09-30 |
2023-03-14 |
佛山市第一人民医院(中山大学附属佛山医院) |
一种器官保存液
|
|
JP2025502209A
(ja)
*
|
2022-01-13 |
2025-01-24 |
フィブロジェン インコーポレイテッド |
うっ血性心不全の処置
|
|
WO2024165507A1
(en)
|
2023-02-06 |
2024-08-15 |
Institut National de la Santé et de la Recherche Médicale |
Use of hif-1α stabilizing agents for the treatment of type i interferonopathies
|
|
WO2026015709A1
(en)
*
|
2024-07-10 |
2026-01-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Covalent inhibitors of jak2 jh2 domain
|